Inari Medical, Inc. (NARI)
NASDAQ: NARI · IEX Real-Time Price · USD
49.80
-0.39 (-0.78%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Inari Medical Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Inari Medical stock have an average target of 65.71, with a low estimate of 50 and a high estimate of 84. The average target predicts an increase of 31.95% from the current stock price of 49.80.
Analyst Consensus: Buy
* Price targets were last updated on May 1, 2024.
Analyst Ratings
The average analyst rating for Inari Medical stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $75 → $55 | Strong Buy | Maintains | $75 → $55 | +10.44% | May 1, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $100 → $84 | Buy | Maintains | $100 → $84 | +68.67% | May 1, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $55 → $50 | Hold | Maintains | $55 → $50 | +0.40% | May 1, 2024 |
| Needham | Needham | Strong Buy Maintains $72 → $57 | Strong Buy | Maintains | $72 → $57 | +14.46% | May 1, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +50.60% | Apr 12, 2024 |
Financial Forecast
Revenue This Year
610.56M
from 493.63M
Increased by 23.69%
Revenue Next Year
721.43M
from 610.56M
Increased by 18.16%
EPS This Year
-0.51
from -0.03
EPS Next Year
0.25
from -0.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 630.8M | 762.1M | 912.5M | 1.0B |
| Avg | 610.6M | 721.4M | 846.9M | 1.0B |
| Low | 585.1M | 682.9M | 787.9M | 966.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 27.8% | 24.8% | 26.5% | 22.3% |
| Avg | 23.7% | 18.2% | 17.4% | 18.8% |
| Low | 18.5% | 11.8% | 9.2% | 14.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.25 | 0.93 | 1.81 | 0.95 |
| Avg | -0.51 | 0.25 | 0.78 | 0.92 |
| Low | -0.76 | 0.05 | 0.36 | 0.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | 620.6% | 21.6% |
| Avg | - | - | 210.1% | 18.1% |
| Low | - | - | 44.7% | 13.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.